AVI BioPharma to Present at BMO Healthcare Conference
August 04 2008 - 9:30AM
Marketwired
CORVALLIS, OR , a developer of RNA-based drugs, today announced
that Dr. Leslie Hudson, CEO, will present an update on the
transitioning of AVI from an antisense pioneer into an RNA-based
drug discovery and development company. The corporate overview will
include an update on AVI's clinical trials in Duchenne muscular
dystrophy, its biodefense projects -- which include significant
data from our ongoing Ebola and Marburg virus programs -- its
partnership with Cook Medical in the development of a drug eluting
stent for cardiovascular restenosis and the company's renewed focus
on partnership and collaboration to develop other promising
applications and programs within AVI.
The BMO Capital Markets Focus on Healthcare Conference runs from
Tuesday, August 5th to Wednesday, August 6th at the Millennium
Broadway Hotel in New York City. Dr. Hudson's presentation is
scheduled to begin at 4:00 PM on Tuesday, August 5.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
RNA-based drugs using the company's expanded portfolio of
proprietary antisense compounds (PMOs). The company's technology
applications leverage distinct mechanisms of action in a range of
genetic diseases, genetic disorders and the genetic code of
disease-causing organisms. The emerging field of directed
alternative RNA splicing represents AVI's newest and most exciting
application based on the company's core antisense technology.
Functional attributes of this approach may include correcting
genetic defects (RNA mutations; which AVI believes could produce
promising treatments for Duchenne muscular dystrophy), coding for
novel soluble receptors (an exciting and novel approach which could
have application in the treatment of inflammatory diseases such as
rheumatoid arthritis), and the reduction in activity of immune
modulators in disease states (currently being applied to IL-10).
AVI's RNA-based drug programs also include blocking mRNA
translation. In AVI's biodefense program, this application has been
successful against the single-stranded RNA viruses Ebola Zaire and
Marburg Musoke in non-human primates and may have value against
other viral targets such as HCV, Dengue, Junin, influenza and RSV
viruses. This application also will be evaluated in the clinic for
the treatment of cardiovascular restenosis by our partner Cook
Medical. More information about AVI is available at
www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Press and Investor Contact: Michael Hubbard (Email Contact)
Director of Corporate Communications (503) 227-0554
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024